Sort
39,280 grants matching “leukemia”
Novel DNA Repair Inhibitors for Cancer Therapy
$984,900Peter M Glazer · Yale University · R35 · FY2022 · CA
Metabolic gatekeepers in B-cell malignancies
$984,900Markus Mãschen · Yale University · R35 · FY2022 · CA
Metabolic gatekeepers in B-cell malignancies
$984,894Markus Mãschen · Yale University · R35 · FY2023 · CA
Metabolic regulation of T cell effector function and anti-tumor immunotherapy
$984,739Naomi Taylor · Division Of Basic Sciences - Nci · ZIA · FY2020 · CA
Hematopoietic Chimerism after Stem Cell Allografts
$984,084Rainer F. Storb · Fred Hutchinson Cancer Research Center · P01 · FY2019 · CA
Biomolecular Recognition and Binding Mechanisms
$984,067Ruth Nussinov · Division Of Basic Sciences - Nci · ZIA · FY2025 · CA
Radioimmunotherapy Based Transplant Regimens for Treatment of B-Cell Lymphoma and
$983,786Stephen J Forma · Beckman Research Institute/City Of Hope · P01 · FY2007 · CA
Mechanisms of Transcriptional Control by p300
$983,591Kevin Gardner · Division Of Basic Sciences - Nci · Z01 · FY2008 · CA
Viral And Cellular Factors Governing Efficient Gene Delivery
$983,499Maribeth V. Eiden · National Institute Of Mental Health · ZIA · FY2009 · MH
Adaptable and scalable electroporation for cellular therapy
$983,392Harold G Craighead · Cytequest, Inc. · R44 · FY2025 · GM
Molecular Pathogenesis of Neoplasia
$983,208Richard Youle · National Institute Of Neurological Disorders And Stroke · ZIA · FY2018 · NS
Clinical, Immunological and Genetic Analyses of ALPS and Related Immunedysregulatory Disorders
$982,917Vemulkonda Rao · National Institute Of Allergy And Infectious Diseases · ZIA · FY2022 · AI
Functional and translational studies of RUNX1 and CBFB in hematopoiesis
$982,801Paul Liu · National Human Genome Research Institute · ZIA · FY2019 · HG
Mechanistic and translational studies of CBF leukemia
$982,801Paul Liu · National Human Genome Research Institute · ZIA · FY2019 · HG
A phase IIA trial for the safety and tolerability of CD24Fc in prophylaxis of graft vs host disease.
$982,509Martin Devenport · Oncoimmune, Inc. · R44 · FY2018 · CA
New Paradigms for Targeting Truncal Driver Mutations
$982,500William G Kaelin · Dana-Farber Cancer Inst · R35 · FY2021 · CA
New Paradigms for Targeting Truncal Driver Mutations
$982,500William G Kaelin · Dana-Farber Cancer Inst · R35 · FY2020 · CA
Pathway Discovery and Target Validation for Outgrowth of Breast Cancer Metastases
$982,500Joel S. Bader · Johns Hopkins University · U01 · FY2021 · CA
Pathway Discovery and Target Validation for Outgrowth of Breast Cancer Metastases
$982,500Joel S. Bader · Johns Hopkins University · U01 · FY2020 · CA
New Paradigms for Targeting Truncal Driver Mutations
$982,500William G Kaelin · Dana-Farber Cancer Inst · R35 · FY2017 · CA
New Paradigms for Targeting Truncal Driver Mutations
$982,500William G Kaelin · Dana-Farber Cancer Inst · R35 · FY2016 · CA
Novel DNA Repair Inhibitors for Cancer Therapy
$982,379Peter M Glazer · Yale University · R35 · FY2023 · CA
Gene therapy for SCID-X1 with low dose busulfan and a SIN-lentiviral vector
$982,311David A Williams · Boston Children'S Hospital · U01 · FY2020 · AI
Viral And Cellular Factors Governing Efficient Gene Delivery
$982,268Maribeth V. Eiden · National Institute Of Mental Health · ZIA · FY2011 · MH
A novel glycan-based selectin and complement inhibitor for at-home disease-modifying rescue of pain crisis in sickle cell disease
$982,081John Paderi John Paderi John Paderi · Ihp Therapeutics, Inc. · UH3 · FY2025 · NS